These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16216724)

  • 1. Implications of emerging risk factors for therapeutic intervention.
    Assmann G; Cullen P; Fruchart JC; Greten H; Naruszewicz M; Olsson A; Paoletti R; Riesen W; Stoll M; Tikkanen M; von Eckardstein A;
    Nutr Metab Cardiovasc Dis; 2005 Oct; 15(5):373-81. PubMed ID: 16216724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
    Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
    Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
    Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
    Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
    Davidson MH; Maki KC; Pearson TA; Pasternak RC; Deedwania PC; McKenney JM; Fonarow GC; Maron DJ; Ansell BJ; Clark LT; Ballantyne CM
    Am J Cardiol; 2005 Aug; 96(4):556-63. PubMed ID: 16098311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rising to the challenge of treating high-risk patients.
    Guthrie RM
    Am J Manag Care; 2006 Oct; 12(11 Suppl):S318-24. PubMed ID: 17042674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.
    Clearfield M; Downs JR; Lee M; Langendorfer A; McConathy W; Gotto AM
    Am J Cardiol; 2005 Dec; 96(12):1674-80. PubMed ID: 16360356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002.
    Cullen MW; Stein JH; Gangnon R; McBride PE; Keevil JG
    Am Heart J; 2008 Aug; 156(2):284-91. PubMed ID: 18657658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile.
    Blackburn P; Lemieux I; Alméras N; Bergeron J; Côté M; Tremblay A; Lamarche B; Després JP
    Metabolism; 2009 Aug; 58(8):1123-30. PubMed ID: 19481769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol. How low should we go?
    Chamsi-Pasha H
    Saudi Med J; 2005 Jan; 26(1):11-8. PubMed ID: 15756346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia.
    Persell SD; Lloyd-Jones DM; Baker DW
    J Gen Intern Med; 2006 Feb; 21(2):171-6. PubMed ID: 16390501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
    Hildemann S; Karmann B; Pittrow D; Barho C; Darius H; Bode C
    Curr Med Res Opin; 2008 Jun; 24(6):1659-68. PubMed ID: 18457604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS
    Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
    Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
    J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
    MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
    Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS
    Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.